Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Abstract

In this study, acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation. (Funded by the National Institutes of Health and others.).

Keywords

MedicineMelanomaContext (archaeology)PembrolizumabImmunotherapyCancerCancer researchImmune checkpointImmunologyOncologyInternal medicineBiology

MeSH Terms

AntibodiesMonoclonalHumanizedAntineoplastic AgentsBiopsyDrug ResistanceNeoplasmExomeGene Expression RegulationNeoplasticGenesMHC Class IHumansImmunotherapyInterferon-gammaJanus Kinase 1Janus Kinase 2MelanomaMutationProgrammed Cell Death 1 ReceptorRecurrenceSequence AnalysisDNASignal Transductionbeta 2-Microglobulin

Affiliated Institutions

Related Publications

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimu...

2015 New England Journal of Medicine 7913 citations

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Valsamo Anagnostou , Kellie N. Smith , Patrick M. Forde +26 more

Abstract Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the ...

2016 Cancer Discovery 853 citations

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Mohammad Atefi , Earl Avramis , Amanda Lassen +9 more

Abstract Purpose: PD-L1 is the main ligand for the immune inhibitory receptor PD-1. This ligand is frequently expressed by melanoma cells. In this study, we investigated whether...

2014 Clinical Cancer Research 323 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations

Daniel Sanghoon Shin , Jesse M. Zaretsky , Helena Escuin-Ordinas +24 more

Abstract Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in pr...

2016 Cancer Discovery 1216 citations

Publication Info

Year: 2016
Type: article
Volume: 375
Issue: 9
Pages: 819-829
Citations: 2998
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2998

OpenAlex

Influential

2700

CrossRef

Cite This

APA Style

                            
                                
                                    Jesse M. Zaretsky, 
                                
                                    Ángel García-Díaz, 
                                
                                    Daniel Sanghoon Shin
                                
                                et al.
                            
                            (2016). 
                            Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. 
                            New England Journal of Medicine
                            , 375
                            (9)
                            , 819-829.
                            https://doi.org/10.1056/nejmoa1604958
                        

Identifiers

DOI: 10.1056/nejmoa1604958
PMID: 27433843
PMCID: PMC5007206

Data Quality

Data completeness: 86%